Table 1.

Characteristic of included stduies.

study	Total patients	Serious adverse events	The overall rate of adverse events	Nusinersen-related adverse events	May be related to drugs	Upper respiratory tract infection	Pneumonia	Vomiting	Constipation	Diarrhea	Feve	Pain	Cough	Respiratory failur	Gastroesophageal reflux disease	Atelectasis	Dysphagia	Aspiration pneumonia	Respiratory distress	Nasopharyngitis	Skin rash	Otitis media	Thrombocytopenia	Post–lumbar Puncture Syndrome (PLPS)
Finkel RS[11]2017	80	45	77	N	N	24	23	14	28	N	45	N	14	20	10	18	8	8	21	N	N	N	N	N
Konersman CG[12]2021	19	N	N	N	N	2	3	4	0	5	5	4	3	3	0	0	1	1	2	0	0	1	0	N
De Vivo DC[13]2019	25	12	25	0	8	19	6	10	6	7	21	N	13	N	N	N	N	N	N	7	N	7	0	8
Darras BT[14]2019	240	99	231	1	41	90	40	58	49	N	114	47	43	28	N	25	N	N	34	59	N	N	38	27
Acsadi G[15]2021	20	10	20	0	2	12	13	10	4	6	16	8	14	4	N	N	N	N	4	N	N	N	1	N
Szabó L[16]2020	54	N	N	0	1	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	1	3
Pechmann A[17]2018	61	29	53	N	N	31	N	N	N	N	N	N	N	8	N	N	N	N	N	N	3	N	N	3
Audic F[18]2020	25	N	N	N	N	N	N	4	N	N	1	2	N	N	N	N	N	N	N	N	N	N	N	6
Chiriboga CA[19]2016	28	5	25	0	2	5	N	3	3	N	4	7	N	N	3	N	N	N	N	N	N	N	N	12
Mercuri E[20]2018	84	14	78	N	N	25	N	24	N	N	36	45	21	N	N	N	N	N	N	24	0	0	0	8
Osredkar D[21]2021	61	0	24	13	13	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10
Finkel RS[22]2021	20	16	20	0	0	12	8	8	9	N	17	4	9	8	6	11	N	N	N	8	12	8	N	N
Haché M[23]2016	28	N	20	N	N	N	N	1	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9
Sansone VA[24]2019	50	N	N	0	0	N	N	3	N	N	3	N	N	N	N	N	N	N	N	N	N	N	N	3
Wataya T[25]2021	172	23	67	N	N	N	30	N	N	N	34	25	N	N	N	N	N	N	N	N	N	N	N	12

N, not mentioned.